collection
https://read.qxmd.com/read/37845118/respiratory-involvement-in-connective-tissue-diseases
#21
REVIEW
Panagiota Xanthouli, Ishan Echampati, Hanns-Martin Lorenz, Claus Peter Heussel, Nicola Benjamin
Pulmonary involvement is doubtless one the most fatal organ manifestations of the autoimmune rheumatic diseases (ARD) and involves the parenchyma, the vessels, the respiratory system itself, but also the muscles and the pleura. Close and regular screening assessments, identification of risk factors, clinical signs associated with the existence of lung disease should alarm the involved physicians treating these patients. The accurate classification is essential, as different treatment options are nowadays available...
October 14, 2023: European Journal of Internal Medicine
https://read.qxmd.com/read/37479496/systematic-literature-review-informing-the-2022-update-of-the-eular-recommendations-for-the-management-of-anca-associated-vasculitis-aav-part-1-treatment-of-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis
#22
JOURNAL ARTICLE
Jan Henrik Schirmer, Beatriz Sanchez-Alamo, Bernhard Hellmich, David Jayne, Sara Monti, Raashid Ahmed Luqmani, Gunnar Tomasson
OBJECTIVE: To summarise and update evidence to inform the 2022 update of the EULAR recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis (AAV). METHODS: A systematic literature review (SLR) was performed to identify current evidence regarding treatment of AAV. PubMed, EMBASE and the Cochrane library were searched from 1 February 2015 to 25 February 2022. The evidence presented here is focused on the treatment of granulomatosis with polyangiitis and microscopic polyangiitis...
July 2023: RMD Open
https://read.qxmd.com/read/37851380/toward-targeted-treatments-for-silicosis
#23
REVIEW
Hayley Barnes, Maggie Lam, Michelle D Tate, Ryan Hoy
PURPOSE OF REVIEW: There has been a rapid increase in silicosis cases, particularly related to artificial stone. The key to management is avoidance of silica exposure. Despite this, many develop progressive disease and there are no routinely recommended treatments. This review provides a summary of the literature pertaining to pharmacological therapies for silicosis and examines the plausibility of success of such treatments given the disease pathogenesis. RECENT FINDINGS: In-vitro and in-vivo models demonstrate potential efficacy for drugs, which target inflammasomes, cytokines, effector cells, fibrosis, autophagy, and oxidation...
March 1, 2024: Current Opinion in Pulmonary Medicine
https://read.qxmd.com/read/37823528/interstitial-lung-diseases-in-inborn-errors-of-immunity
#24
REVIEW
Neal P Sullivan, Nivethietha Maniam, Paul J Maglione
PURPOSE OF REVIEW: Our goal is to review current understanding of interstitial lung disease (ILD) affecting patients with inborn errors of immunity (IEI). This includes understanding how IEI might predispose to and promote development or progression of ILD as well as how our growing understanding of IEI can help shape treatment of ILD in these patients. Additionally, by examining current knowledge of ILD in IEI, we hope to identify key knowledge gaps that can become focus of future investigative efforts...
December 1, 2023: Current Opinion in Allergy and Clinical Immunology
https://read.qxmd.com/read/37947275/anca-associated-vasculitis-treatment-standard
#25
JOURNAL ARTICLE
Aglaia Chalkia, David Jayne
ANCA-associated Vasculitides (AAV) are characterized by small vessel necrotizing inflammation and prior to the advent of immunosuppressive therapy frequently had a fatal outcome. Treatment has transformed AAV into a relapsing/remitting disease with increased drug-related toxicities and organ damage. The use of glucocorticoids, cyclophosphamide and immunosuppressives (including azathioprine, mycophenolate, methotrexate) was optimised through a sequence of clinical trials establishing a standard of care against which subsequent targeted therapies could be developed...
November 8, 2023: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/37923862/systemic-sclerosis-interstitial-lung-disease-unmet-needs-and-potential-solutions
#26
REVIEW
Vasiliki Liakouli, Antonio Ciancio, Francesco Del Galdo, Roberto Giacomelli, Francesco Ciccia
Systemic sclerosis (SSc), or scleroderma, is a rare, complex, systemic autoimmune disease of unknown aetiology, characterized by high morbidity and mortality often resulting from cardiopulmonary complications such as interstitial lung disease and pulmonary arterial hypertension. Despite substantial progress in unravelling the pathways involved in the pathogenesis of SSc and the increasing number of therapeutic targets tested in clinical trials, there is still no cure for this disease, although several proposed treatments might limit the involvement of specific organs, thereby slowing the natural history of the disease...
January 2024: Nature Reviews. Rheumatology
https://read.qxmd.com/read/37932180/safety-of-readministration-of-egfr-tki-after-onset-of-interstitial-lung-disease-in-advanced-egfr-mutated-nsclc-a-systematic-review-and-meta-analysis
#27
JOURNAL ARTICLE
Fumihiro Kashizaki, Hao Chen, Atsushi Miyasaka, Nanami Tsuchiya, Chihiro Yamada, Shunsuke Okazaki, Mai Kaneko, Taiki Kano, Yohei Kameda, Akitomo Kikuchi, Kentaro Yumoto, Hiroyuki Osawa, Harumi Koizumi, Kenichi Takahashi, Takeshi Kaneko
BACKGROUND: In patients with epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC), EGFR-tyrosine kinase inhibitor (TKI) interruption due to EGFR-TKI-induced interstitial lung disease (ILD) is a factor for shorter overall survival (OS). Several retrospective cohort studies have reported an OS-prolonging effect of the readministration of EGFR-TKIs. This study aimed to determine the safety of readministration of EGFR-TKIs after the onset of EGFR-TKI-induced ILD...
October 5, 2023: Clinical Lung Cancer
https://read.qxmd.com/read/37696313/the-spectrum-of-pulmonary-amyloidosis
#28
REVIEW
Anas Riehani, Ayman O Soubani
Amyloidosis is a disease caused by misfolded proteins that deposit in the extracellular matrix as fibrils, resulting in the dysfunction of the involved organ. The lung is a common target of Amyloidosis, but pulmonary amyloidosis is uncommonly diagnosed since it is rarely symptomatic. Diagnosis of pulmonary amyloidosis is usually made in the setting of systemic amyloidosis, however in cases of localized pulmonary disease, surgical or transbronchial tissue biopsy might be indicated. Pulmonary amyloidosis can be present in a variety of discrete entities...
September 9, 2023: Respiratory Medicine
https://read.qxmd.com/read/37619546/acute-exacerbation-and-proposed-criteria-for-progressive-pulmonary-fibrosis-in-patients-with-fibrotic-hypersensitivity-pneumonitis-and-idiopathic-pulmonary-fibrosis
#29
JOURNAL ARTICLE
Ryo Okuda, Tamiko Takemura, Toshihiro Misumi, Ryo Nagasawa, Tae Iwasawa, Tomohisa Baba, Eri Hagiwara, Takashi Ogura
BACKGROUND: Acute exacerbation (AE) occasionally develops in the course of fibrotic hypersensitivity pneumonitis (HP). OBJECTIVE: The aim of the study was to compare AE of fibrotic HP with that of idiopathic pulmonary fibrosis (IPF). METHODS: Consecutive patients with pathologically confirmed fibrotic HP and IPF diagnosed based on a multidisciplinary discussion were included in the analysis. AE in patients with fibrotic HP and IPF was evaluated retrospectively...
2023: Respiration; International Review of Thoracic Diseases
https://read.qxmd.com/read/37598895/minimal-effective-dose-of-maintenance-steroid-therapy-for-relapse-of-cryptogenic-organizing-pneumonia
#30
JOURNAL ARTICLE
Kenichiro Atsumi, Kakeru Hisakane, Erika Mikami, Takahiro Suzuki, Satoru Matsuki, Masahiro Seike, Takashi Hirose
BACKGROUND: Long-term maintenance steroid therapy (MST) is frequently required for repeated relapses of cryptogenic organizing pneumonia (COP); however, the optimal minimal dose has not been clarified. Therefore, this study evaluated the minimal MST dose required to prevent repeated relapses and identify relapse predictors. METHODS: We retrospectively reviewed the medical records of patients with steroid-treated COP and compared background factors between the non-relapse and relapse groups...
November 2023: Respiratory Medicine
https://read.qxmd.com/read/37591536/telomere-length-and-immunosuppression-in-non-idiopathic-pulmonary-fibrosis-interstitial-lung-disease
#31
JOURNAL ARTICLE
David Zhang, Ayodeji Adegunsoye, Justin M Oldham, Julia Kozlitina, Nicole Garcia, Maria Poonawalla, Rachel Strykowski, Angela L Linderholm, Brett Ley, Shwu-Fan Ma, Imre Noth, Mary E Strek, Paul J Wolters, Christine Kim Garcia, Chad A Newton
BACKGROUND: Studies suggest a harmful pharmacogenomic interaction exists between short leukocyte telomere length (LTL) and immunosuppressants in idiopathic pulmonary fibrosis (IPF). It remains unknown if a similar interaction exists in non-IPF interstitial lung disease (ILD). METHODS: A retrospective, multicentre cohort analysis was performed in fibrotic hypersensitivity pneumonitis (fHP), unclassifiable ILD (uILD) and connective tissue disease (CTD)-ILD patients from five centres...
November 2023: European Respiratory Journal
https://read.qxmd.com/read/37590496/supplemental-oxygen-therapy-in-interstitial-lung-disease-a-narrative-review
#32
REVIEW
Kristopher P Clark, Howard B Degenholtz, Kathleen O Lindell, Daniel J Kass
Patients with interstitial lung diseases (ILD) often have hypoxemia at rest and/or with exertion, for which supplemental oxygen is commonly prescribed. The number of patients with ILD who require supplemental oxygen is unknown, although estimates suggest it could be as much as 40%; many of these patients may require high-flow support (>4 L/min). Despite its frequent use, there is limited evidence for the impact of supplemental oxygen on clinical outcomes in ILD, with recommendations for its use primarily based on older studies in patients with chronic obstructive pulmonary disease...
November 2023: Annals of the American Thoracic Society
https://read.qxmd.com/read/37582424/impact-of-systemic-sclerosis-associated-interstitial-lung-disease-with-and-without-pulmonary-hypertension-on-survival-a-large-cohort-study-of-the-german-network-for-systemic-sclerosis
#33
JOURNAL ARTICLE
Pia Moinzadeh, Francesco Bonella, Max Oberste, Jithmi Weliwitage, Nobert Blank, Gabriela Riemekasten, Ulf Müller-Ladner, Jörg Henes, Elise Siegert, Claudia Günther, Ina Kötter, Christiane Pfeiffer, Marc Schmalzing, Gabriele Zeidler, Peter Korsten, Laura Susok, Aaron Juche, Margitta Worm, Ilona Jandova, Jan Ehrchen, Cord Sunderkötter, Gernot Keyßer, Andreas Ramming, Tim Schmeiser, Alexander Kreuter, Hanns-Martin Lorenz, Nicolas Hunzelmann, Michael Kreuter
BACKGROUND: Pulmonary involvement is the leading cause of death in systemic sclerosis (SSc) and may manifest as interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), or in combination of both (ILD with pulmonary hypertension [ILD-PH]). The aim of this analysis was to determine prevalence, clinical characteristics, and survival of these different forms within the registry of the German Network for Systemic Sclerosis. RESEARCH QUESTION: Does SSc-associated ILD-PH or ILD without PH affect survival differently, and are there any risk factors that have an additional impact? STUDY DESIGN AND METHODS: Clinical data of 5,831 patients with SSc were collected in the German Network for Systemic Sclerosis registry...
January 2024: Chest
https://read.qxmd.com/read/37534937/prevalence-risk-factors-and-outcomes-of-adult-interstitial-lung-abnormalities-a-systematic-review-and-meta-analysis
#34
JOURNAL ARTICLE
Amanda Grant-Orser, Bohyung Min, Seham Elmrayed, Anna J Podolanczuk, Kerri A Johannson
Rationale: Incidental parenchymal abnormalities detected on chest computed tomography scans are termed interstitial lung abnormalities (ILAs). ILAs may represent early interstitial lung disease (ILD) and are associated with an increased risk of progressive fibrosis and mortality. The prevalence of ILAs is unknown, with heterogeneity across study populations. Objectives: Estimate the pooled prevalence of ILAs in lung cancer screening, general population-based, and at-risk familial cohorts using meta-analysis; identify variables associated with ILA risk; and characterize ILA-associated mortality...
September 15, 2023: American Journal of Respiratory and Critical Care Medicine
https://read.qxmd.com/read/37121779/contemporary-concise-review-2022-interstitial-lung-disease
#35
REVIEW
David J F Smith, R Gisli Jenkins
Novel genetic associations for idiopathic pulmonary fibrosis (IPF) risk have been identified. Common genetic variants associated with IPF are also associated with chronic hypersensitivity pneumonitis. The characterization of underlying mechanisms, such as pathways involved in myofibroblast differentiation, may reveal targets for future treatments. Newly identified circulating biomarkers are associated with disease progression and mortality. Deep learning and machine learning may increase accuracy in the interpretation of CT scans...
July 2023: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://read.qxmd.com/read/37505195/imaging-features-of-idiopathic-interstitial-lung-diseases
#36
REVIEW
Kiran Batra, Traci N Adams
Idiopathic interstitial pneumonias (IIPs) are a group of diffuse parenchymal lung diseases of unclear etiology and are distinguished from diffuse parenchymal lung diseases of known cause, such as connective tissue disease-related interstitial lung diseases or hypersensitivity pneumonitis by history, physical exam, imaging, serologic testing, and, when necessary, histopathology. The 2013 American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines are the most widely accepted classification of IIPs and include the following diagnoses: idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, idiopathic lymphocytic interstitial pneumonia, idiopathic pleuro-parenchymal fibroelastosis, respiratory bronchiolitis-interstitial lung disease, and desquamative interstitial pneumonia...
November 1, 2023: Journal of Thoracic Imaging
https://read.qxmd.com/read/37199348/new-paradigm-in-the-treatment-of-myositis-associated-interstitial-lung-disease
#37
REVIEW
Takahisa Gono, Masataka Kuwana
INTRODUCTION: Interstitial lung disease (ILD) is the leading cause of mortality in idiopathic inflammatory myopathies or myositis. Clinical characteristics, including the course of ILD, rate of progression, radiological and pathohistological morphologies, extent and distribution of inflammation and fibrosis, responses to treatment, recurrence rate, and prognosis, are highly variable among myositis patients. A standard practice for ILD management in myositis patients has not yet been established...
May 2023: Expert Review of Respiratory Medicine
https://read.qxmd.com/read/37395510/interstitial-lung-disease-in-patients-with-anti-neutrophil-cytoplasm-antibody-associated-vasculitis-an-update-on-pathogenesis-and-treatment
#38
REVIEW
David Turgeon, Meyer S Balter, Christian Pagnoux
PURPOSE OF REVIEW: Interstitial lung disease (ILD) is now recognized as a common complication of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), especially myeloperoxidase (MPO)-ANCA-positive AAV and microscopic polyangiitis (MPA). This review focuses on current concepts pertaining to the pathogenesis, clinical assessment, and management of AAV-ILD. RECENT FINDINGS: ILD is typically identified before or at the onset of systemic AAV, and usual interstitial pneumonia (UIP) is the most common CT pattern...
September 1, 2023: Current Opinion in Pulmonary Medicine
https://read.qxmd.com/read/37417835/interstitial-lung-disease-associated-pulmonary-hypertension-what-the-future-holds
#39
REVIEW
Vincent Cottin, Rémi Diesler, Ségolène Turquier, Claudia Valenzuela
PURPOSE OF REVIEW: Pulmonary hypertension associated with interstitial lung disease (ILD-PH) is associated with significant alteration of quality of life, exercise capacity, and survival. Over the past 2 years, there were changes in the guideline definition and classification of ILD-PH, and positive randomized controlled trials were published. RECENT FINDINGS: Pulmonary hypertension associated with chronic lung disease is now hemodynamically defined as a mean pulmonary artery pressure more than 20 mmHg, with pulmonary artery wedge pressure 15 mmHg or less, and pulmonary vascular resistance (PVR) at least 2 Wood units...
September 1, 2023: Current Opinion in Pulmonary Medicine
https://read.qxmd.com/read/37417940/patterns-of-progression-in-non-ipf-fibrotic-interstitial-lung-disease
#40
REVIEW
Athol U Wells
PURPOSE OF REVIEW: To characterize patterns of disease progression in the designation of progressive pulmonary fibrosis (PPF), including their relative prevalence and subsequent prognostic significance, in patients with fibrotic interstitial lung disease (ILD), including key patient sub-groups. RECENT FINDINGS: In recent large clinical cohorts, PPF criteria suited to early PPF identification, based on their prevalence and short time to progression, include a relative forced vital capacity (FVC) decline exceeding 10% and various combinations of lower thresholds for FVC decline, symptomatic worsening and serial progression of fibrosis on imaging...
September 1, 2023: Current Opinion in Pulmonary Medicine
label_collection
label_collection
5856
2
3
2023-07-23 20:52:56
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.